Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8283032 | 1.00 | CYP3A4 (0.40) | CYP3A4CYP2D6CNR2HTTCYP1A2 | |
| SCHEMBL761869 | 1.00 | CYP3A4 (0.40) | CYP3A4CYP2D6CNR2HTTCYP1A2 | |
| SCHEMBL21515942 | 0.98 | HTT (0.39) | CYP3A4CYP2D6CNR2HTTCYP1A2 | |
| SCHEMBL890138 | 0.93 | — | — | |
| SCHEMBL412333 | 0.93 | — | — | |
| SCHEMBL8291028 | 0.93 | — | — | |
| SCHEMBL28845774 | 0.84 | CYP3A4 (0.41) | CYP3A4CYP2D6CNR2CYP1A2CA12 | |
| SCHEMBL7800989 | 0.83 | — | — | |
| SCHEMBL8291026 | 0.83 | — | — | |
| SCHEMBL58093 | 0.82 | ACE (0.42) | CYP3A4CYP2D6CNR2HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296943-A1 | AMINE-CONTAINING VINYLDISILOXANES IN THE MANUFACTURE OF ELASTOMERIC POLYMERS | SYNTHOS DWORY 7 SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (PL) | 2025-09-25 | — | — | US | disclosed |
| EP-4441057-A1 | AMINE-CONTAINING VINYLDISILOXANES IN THE MANUFACTURE OF ELASTOMERIC POLYMERS | Trinseo Europe GmbH (CH) | 2024-10-09 | — | — | EP | disclosed |
| CN-118339169-A | Amine-containing vinyldisiloxane in elastomeric polymer manufacture | 盛禧奥欧洲有限责任公司 | 2024-07-12 | — | — | CN | disclosed |
| WO-2023122228-A1 | NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF | ADCENTRX THERAPEUTICS INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023099462-A1 | AMINE-CONTAINING VINYLDISILOXANES IN THE MANUFACTURE OF ELASTOMERIC POLYMERS | TRINSEO EUROPE GMBH (CH) | 2023-06-08 | — | — | WO | disclosed |
| EP-4186911-A1 | AMINE-CONTAINING VINYLDISILOXANES IN THE MANUFACTURE OF ELASTOMERIC POLYMERS | Trinseo Europe GmbH (CH) | 2023-05-31 | — | — | EP | disclosed |
| WO-2023081230-A1 | NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF | ADCENTRX THERAPEUTICS INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2022079428-A1 | LINEAR APELIN RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022079426-A1 | CYCLIC APELIN RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-04-21 | — | — | WO | disclosed |
| US-11072634-B2 | Inhibitors of transglutaminases | ZEDIRA GMBH (DE) | 2021-07-27 | — | — | US | disclosed |
| US-20100222585-A1 | PREPARATION OF DIHYDROTHIENO [3, 2-D] PYRIMIDINES AND INTERMEDIATES USED THEREIN | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20090111755-A1 | METHODS FOR THE USE OF INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES | PROVID PHARMACEUTICALS, INC. | 2009-04-30 | — | — | US | disclosed |
| US-7439231-B2 | Inhibitors of antigen presentation by MHC class II molecules and methods of use thereof | PROVID PHARMACEUTICALS, INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-24 | — | — | US | disclosed |
| WO-2007067537-A1 | PYRROLOPYRIDINE KINASE INHIBITING COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20070004646-A1 | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004646-A1 | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | CYP3A4 609/4885CYP2D6 2291/4885CNR2 2543/4885 |
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | PDE4A, PDE4B, PDE12 | CYP3A4 47/4885CYP2D6 191/4885CNR2 1021/4885 |
| US-20070004646-A1 | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, ANPEP | CYP3A4 1898/4885CYP2D6 3171/4885CNR2 4520/4885 |
| US-20100222585-A1 | PREPARATION OF DIHYDROTHIENO [3, 2-D] PYRIMIDINES AND INTERMEDIATES USED THEREIN | DPYD, TYMS, DHFR | CYP3A4 826/4885CYP2D6 194/4885CNR2 2199/4885 |
| US-20250296943-A1 | AMINE-CONTAINING VINYLDISILOXANES IN THE MANUFACTURE OF ELASTOMERIC POLYMERS | VARS1, VCL, TYK2 | CYP3A4 2329/4885CYP2D6 3487/4885CNR2 2363/4885 |
| US-20090111755-A1 | METHODS FOR THE USE OF INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES | HLA-DRB1, CD74, MICA | CYP3A4 4591/4885CYP2D6 2904/4885CNR2 3194/4885 |
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | BMX, ERBB2, FRK | CYP3A4 4570/4885CYP2D6 4555/4885CNR2 2809/4885 |
| US-11072634-B2 | Inhibitors of transglutaminases | TGM2, TGM3, TGM1 | CYP3A4 1756/4885CYP2D6 933/4885CNR2 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.